Finland-based TILT Biotherapeutics Ltd has raised €22 million to advance its pipeline of oncolytic viruses to treat cancer. The immunotherapies have been equipped with molecules, including cytokines, that can be delivered locally and systemically to modify the tumour microenvironment and prevent the suppression of immune responses to cancer. The funding will enable the company to advance a group of candidate therapies, including the lead asset TILT-123, in clinical trials. This will be done in combination with immune checkpoint inhibitors.
